Praktické lékárenství – 2/2019

www.praktickelekarenstvi.cz e10 KLINICKÁ FARMACIE AKUTNÍ HEPATOTOXICITA PO INTRAVENÓZNÍ APLIKACI AMIODARONU PRAKTICKÉ LÉKÁRENSTVÍ tes in mice. Clin Cancer Res. 1999; 5(10): 2918–2924. 16. Jaiswal P, Attar BM, Yap JE, et al. Acute liver failure with amiodarone infusion: A case re- port and systematic review. J Clin Pharm Ther. 2018; 43(1): 129–133. 17. Breuer HW, Bossek W, Haferland C, et al. Amiodarone-induced severe hepatitis media- ted by immunological mechanisms. Int J Clin Pharmacol Ther. 1998; 36(6): 350–352. 18. Lu J, Jones AD, Harkema JR, et al. Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha. Toxicol Sci. 2012; 125(1): 126–133. 19. Morelli S, Guido V, De Marzio P, et al. Early hepatitis during intravenous amiodarone ad- ministration. Cardiology. 1991; 78(3): 291–294. 20. Henrion J, Schapira M, Luwaert R, et al. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore). 2003; 82(6): 392–406. 21. Gluck N, Fried M, Porat R. Acute amiodarone liver toxicity likely due to ischemic hepa- titis. Isr Med Assoc J. 2011; 13(12): 748–752. 22. Guglin M. Intravenous amiodarone: offender or bystander? Crit Care Med. 2005; 33(1): 245–246.